AU4973800A - Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist - Google Patents

Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist

Info

Publication number
AU4973800A
AU4973800A AU49738/00A AU4973800A AU4973800A AU 4973800 A AU4973800 A AU 4973800A AU 49738/00 A AU49738/00 A AU 49738/00A AU 4973800 A AU4973800 A AU 4973800A AU 4973800 A AU4973800 A AU 4973800A
Authority
AU
Australia
Prior art keywords
antipsychotic
antagonist
combination
weight gain
gain associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49738/00A
Inventor
Jane Rogers Todd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4973800A publication Critical patent/AU4973800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
AU49738/00A 1999-06-09 2000-05-22 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist Abandoned AU4973800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13831599P 1999-06-09 1999-06-09
US60138315 1999-06-09
PCT/US2000/009811 WO2000074784A1 (en) 1999-06-09 2000-05-22 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist

Publications (1)

Publication Number Publication Date
AU4973800A true AU4973800A (en) 2000-12-28

Family

ID=22481488

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49738/00A Abandoned AU4973800A (en) 1999-06-09 2000-05-22 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist

Country Status (3)

Country Link
EP (1) EP1189662A1 (en)
AU (1) AU4973800A (en)
WO (1) WO2000074784A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2856596B1 (en) * 2003-06-27 2007-04-27 Bioprojet Soc Civ NOVEL PSYCHIATRIC DRUG ASSOCIATION AND THE USE OF AN INVERSE HISTAMINE H3 RECEPTOR ANTAGONIST OR AGONIST TO PREPARE A MEDICAMENT PREVENTING ADVERSE EFFECTS OF PSYCHOTROPES.
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
AU8194991A (en) * 1990-07-06 1992-02-04 Smithkline Beecham Plc Use of cimetidine for weight loss
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia
AU4855393A (en) * 1992-09-10 1994-03-29 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
EP1189662A1 (en) 2002-03-27
WO2000074784A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
AU5270600A (en) The maize rs324 promoter and methods for use thereof
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
IL137328A0 (en) Triazole and imidazole derivatives
AU1006401A (en) Device for supporting and stabilizing an injured person
AU7734700A (en) Macrocyclic quinazolinones and their use as local anesthetics
EP1221885A4 (en) Portable bath seat
IL146629A0 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
AU1303301A (en) Body weight gain inhibitors
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
GB2349433B (en) Sliding bearing and sliding bearing structure
EP1194147A4 (en) Arylthiazolidinedione and aryloxazolidinedione derivatives
AUPQ066399A0 (en) Antifungal combination use
EP1222913A4 (en) Depilatories and agents for external use
AU4384600A (en) Luminescent 4-trifluoromethyl-2-quinolones with long-wave uv-absorption and the use thereof
AU4973800A (en) Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AU5861900A (en) Receptor agonists and antagonists
AU1660201A (en) Biglycan and related therapeutics and methods of use
AU2041901A (en) Genes essential for microbial proliferation and antisense thereto
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU6704100A (en) Oxygen probe
AU4328700A (en) Pseudomycin antifungal compositions and methods for their use
AU2001282913A1 (en) A method of treating weight gain associated with atypical antipsychotic use
AU5974100A (en) 6-carboxyphenyldihydropyridazinone derivatives and use thereof
GB9920670D0 (en) Stabilisation of peroxidases
AU2559100A (en) An umbrella and container for an umbrella

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase